Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OvaRex misses ovarian cancer endpoint

United Therapeutics (UTHR) and ViRexx (TSX:VIR; REX) said OvaRex oregovomab missed the

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE